window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

preclinical development

  • CDMOs & Manufacturing,Drug Development,Manufacturing,RNA Therapeutics

    Codexis signs siRNA manufacturing deal for cardiovascular programme

    Codexis has signed an agreement to manufacture siRNA for a [...]

    March 23, 2026
  • Clinical Development,Drug Development,European biotech,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

    Syngene International has entered a collaboration with Johns Hopkins University [...]

    February 12, 2026
  • Biologics & Biosimilars,Biotech,Drug Development,Oncology,Pharmaceuticals and therapeutics,Technology and platforms

    Bio‑Sourcing and Zerion Pharma collaborate on first oral HER2 monoclonal antibody

    Bio‑Sourcing and Zerion Pharma have joined forces to develop the [...]

    January 12, 2026
  • Biotech,Drug Development,Immunology,Research & Development

    Nucleome Therapeutics nominates first preclinical development candidate for inflammatory diseases

    Nucleome Therapeutics has nominated its first preclinical development candidate, marking [...]

    January 8, 2026
  • Biologics & Biosimilars,Clinical Development,Clinical studies,Global health,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    PACE launches third funding round to tackle antimicrobial resistance and support innovative therapeutics

    PACE (Pathways to Antimicrobial Clinical Efficacy) has launched its third [...]

    October 1, 2025
  • Biologics & Biosimilars,Biotech,Partnerships & Funding,Rare Diseases,Research & Development

    DEBRA Research and Nonsense Therapeutics launch ReadOn Therapeutics to target epidermolysis bullosa

    DEBRA Research gGmbH, a global non-profit dedicated to advancing research [...]

    September 26, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding

    Oxeltis and MFI join forces as $12.8 BN in silico drug discovery market accelerates

    Contract research firm Oxeltis and computational chemistry company Molecular Forecaster [...]

    June 30, 2025
  • Movers & Shakers

    PhoreMost brings in biotech major players with $30B+ in deal history

    Company says appointments of Barbara Duncan and Stephen Dilly will [...]

    May 12, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top